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Men fear thought as they fear nothing else on earth - more than ruin - more even 
than death. Thought is subversive and revolutionary, destructive and terrible, 
thought is merciless to privilege, established institutions, and comfortable habit. 
Thought looks into the pit of hell and is not afraid. Thought is great and swift 
and free, the light of the world, and the chief glory of man.  
Bertrand Russell (1872 – 1970)                                                    
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2. Zusammenfassung 
Electromyogram-Biofeedback bei Patienten mit Fibromyalgie: Eine randomisierte, 
kontrollierte Studie 
Ziel: Untersuchung der Wirksamkeit von EMG-Biofeedback Training bei Fibromyalgiepatienten. 
Design: Als Studiendesign wurde eine randomisierte kontrollierte Pilotstudie mit Verblindung 
des Untersuchers gewählt. Die Datensammlung erfolgte vor Therapiebeginn (T0), nach 
Therapieende (T1) und nach weiteren drei Monaten (T2). 
Einrichtung: Ambulanz. 
Patienten: Patientinnen auf der Warteliste der Tagesklinik für Fibromyalgia, welche die 
Einschlusskriterien erfüllen.  
Intervention: Innerhalb von 8 Wochen 14 Sitzungen mit EMG-Biofeedback Training 
zusätzlich zur herkömmlichen Behandlung versus herkömmliche Behandlung.  
Ergebnismessung und Analysen: Der Hauptzielparameter „krankheitsspezifischer 
Gesundheitszustand“ wurde mit dem Fibromyalgia Impact Questionnaire (FIQ) gemessen. Als 
Nebenzielparameter wurden Daten zu Schmerz (Tender Point Score), Tenderness (Tender 
Point Count = Anzahl der Tender Points, Druckschmerzschwelle), allgemeiner Gesundheit 
(SF-36), subjektiver Einschätzung der Veränderung aus Patientenperspektive (Patients’ 
Global Clinical Impression of Change) und psychischer Beeinträchtigung (Beck 
Depressionsinventar, Symptom Checklist 90-Revised) während des Untersuchungszeitraumes 
erhoben. Effekte wurden durch Sensitivitätsstatistiken (Effect size, ES) sowie parametrische 
und nicht-parametrische Signifikanz-Testung beurteilt.  
Ergebnisse: Die Daten von 36 Patienten mit kompletten Verlaufsdaten konnten analysiert 
werden. Im Verlauf wurde keine Verbesserung des krankheitsspezifischen 
Gesundheitszustandes der Interventionsgruppe im Vergleich zur Kontrolle beobachtet (T1: ES 
= 0,02, p = 0,95, T2: ES = 0,26, p = 0,43). Mit Ausnahme der Druckschmerzschwelle (T1: ES 
= 0,26, p = 0,014) ergaben sich auch in den Nebenzielpararmetern keine signifikanten 
Unterschiede zwischen den Studiengruppen.  
Schlussfolgerung: EMG-Biofeedback Training zusätzlich zur herkömmlichen Behandlung ist 
bei Fibromyalgiapatienten nicht effektiver als herkömmliche Behandlung alleine.  
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3. Abstract 
Electromyogram-Biofeedback in Patients with Fibromyalgia: A Randomized Controlled 
Trial 
 
Objective: To evaluate the effectiveness of EMG-biofeedback in patients with Fibromyalgia. 
Design: The study design was a randomized controlled pilot trial with blinded assessors and 
three points of assessment: before intervention (baseline, T0), at the end of treatment (T1) and 
a 3-months follow-up (T2).  
Setting: Outpatient clinic. 
Patients: Patients from the waiting list of the Fibromyalgia day hospital program fulfilling the 
inclusion criteria. 
Intervention: During eight weeks, 14 sessions of EMG-biofeedback training versus usual 
care only. 
Outcome Measures and Analysis: For primary outcome, the disease specific health status 
was followed using the Fibromyalgia Impact Questionnaire (FIQ). Secondary outcome 
measures comprise assessment of pain (Tender Point Score), tenderness (Tender Point Count 
= number of Tender Points, Pain Pressure Threshold), generic health status (SF-36), Patients’ 
Global Clinical Impression of Change and psychic impact (Beck depression Inventory, 
Symptom Checklist 90-Revised). Effects were analyzed with sensitivity statistics (effect size, 
ES), parametric and nonparametric tests. 
Results: The data of 36 patients with complete follow-up data could be analyzed. EMG-
EMG-biofeedback did not improve health status of patients with Fibromyalgia (FIQ, T1: ES = 
0.02, p = 0.95, T2: ES = 0.26, p = 0.43). Also, the secondary outcome measures, with the 
exception of the pressure pain threshold (T1: ES = 0.26, p = 0.014), showed no superiority of 
EMG-biofeedback in addition to usual care compared to usual care alone.  
Conclusion: In the treatment of patients with Fibromyalgia, EMG-biofeedback training in 
addition to usual medical care is not superior to usual medical care alone. 
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4. Abbreviations 
ACR American College of Rheumatology  
AED Anti-epileptic drug  
AIMS Arthritis Impact Measurement Scales  
BDI Beck Depression Inventory  
CAM Complementary alternative medecine  
CBT Cognitive behavioural therapy  
EMG Electromyogram  
FIQ Fibromyalgia Impact Questionnaire  
FM Fibromyalgia   
FMS Fibromyalgia Syndrome  
CG Control group  
IC Intervention group  
MMPI Minnesota Multiphasic Personality Inventory  
RCT Randomized controlled trial  
SCL-90-R Symptom Checklist 90 Revised  
SCQ Self-administered Comorbidity Questionnaire  
SF-36 Short Form 36  
T0 Baseline  
T1 End of treatment  
T2 3-months follow-up  
TP Tender Point  
TPI Tender Point Index  
TPS Tender Point Score  
VAS Visual analogue scale  
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5. Introduction 
For the past 100 years a disorder characterized by chronic widespread pain, tenderness at 
specific anatomic sites, also known as Tender Points, mood disturbances and vegetative and 
functional symptoms like poor sleep and fatigue has been described. 
In 1904, Sir William Gowers named this condition “Fibrositis” assuming that muscular 
rheumatism is the pathophysiological correlate. In the following decades, researchers in the 
Anglo Saxon and German speech area tried to develop more precise concepts of this 
syndrome. Accordingly, the aetiologically descriptive term “Fibrositis/Fibrositis Syndrome” 
was gradually dropped in favour of symptom-orientated descriptions, such as “Generalized 
Tendomyopathy” in 1970 and “Fibromyalgia Syndrome” in 1976 (Yunus, Masi et al. 1989; 
Muller and Lautenschlager 1990; Muller and Lautenschlager 1990; Inanici and Yunus 2004). 
 
In 1990, Müller and Lautenschläger published extensive clinical criteria for the diagnosis of 
Fibromyalgia based on selected studies and a presentation at the 23rd congress of the German 
Society of Rheumatology. In the same year, Wolfe et al performed a multi-centre study that 
led to the development of the classification criteria of Fibromyalgia Syndrome, endorsed by 
the American College of Rheumatology. These criteria are also known as the ACR-criteria. 
Meanwhile, Fibromyalgia has become a well-established diagnosis and is included in the 
ICD-10 classification (M79.09) (Muller and Lautenschlager 1990; Muller and Lautenschlager 
1990; Wolfe, Smythe et al. 1990). 
 
Despite investigative efforts in the last 20 years, the aetiology remains enigmatic. Research 
groups of various disciplines have proposed different concepts. Some incorporate 
Fibromyalgia among affective disorders, others present arguments which support the idea that 
Fibromyalgia belongs to the field of developmental psychology. There are also groups that 
favour the adoption of a molecularbiological approach (See 5.3 Aetiology, p.14). 
 
Since the pathology and pathophysiology remains unclear, it is not surprising that there is a 
variety of symptom-orientated treatment options. Up to now, a great number of different 
classes of medication, such as antidepressants, non-steroidal anti-inflammatory drugs, opiates, 
muscle relaxants and antiepileptic drugs have been used. There is also a wide range of non-
pharmacological treatments like cognitive-behavioural therapy, exercise programs and 
physical modalities. Today, experts favour a multidisciplinary approach (Forseth and Gran 
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2002; Sprott 2003; Mease 2005; Burckhardt 2006; Arnold, Hauser et al. 2008). 
5.1. Epidemiology and health costs 
The prevalence of Fibromyalgia in the general population in industrialized countries has been 
estimated between 2% und 3% with a peak in the age group from 24 to 50 years. There is a 
gender specific imbalance; women are 6 to 8 times more likely to be affected than men. In 
total, about 6 % of patients in general practices and up to 20 % of patients in rheumatologic 
clinics meet the ACR-criteria for Fibromyalgia. Due to diagnostic uncertainty, it takes 
approximately 7 years from the onset of symptoms to diagnosis. Patients with Fibromyalgia 
often present an extensive health care utilization. In comparison to average medical users, 
they consult a greater number of doctors, undergo more pain-related operations and have more 
pain-related hospital and rehabilitation stays. Certain types of medication, e.g. non-steroidal 
anti-inflammatory drugs and antidepressants, are prescribed more frequently (Conrad 2003; 
Robinson, Birnbaum et al. 2003; Hauser 2005). 
5.2. Symptoms and diagnosis 
Due to symptom complexity, there is no gold standard for the diagnosis of Fibromyalgia. In 
clinical settings, diagnosis is mostly based on the criteria from Müller and Lautenschläger and 
the ACR-criteria developed by Wolfe et al. (Eich, Hauser et al. 2008). 
According to Müller and Lautenschläger, patients with Fibromyalgia have to present chronic 
spontaneous pain in muscles, tendons and their insertions, further positive Tender Points, a 
number of autonomic and functional symptoms, as well as psychopathological findings and 
normal results in routine diagnostic tests (Muller and Lautenschlager 1990). Although the 
ACR-criteria have originally been developed for research purposes, they are frequently used 
as a simple and practical instrument to diagnose Fibromyalgia in the clinic. They have proven 
to have high sensitivity and specificity. The criteria require that patients report chronic 
widespread pain and have at least 11 of 18 typical Tender Points at examination. Pain is 
considered widespread, when it occurs spontaneously in several areas throughout the whole 
body at the same time. A tender point is considered positive, if the digital palpation with a 
force of 4 kg maximum is painful to the patient. Figure 1 displays the locations of the 18 
Tender Points (Wolfe, Smythe et al. 1990).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: Tender point locations (Wolfe, Smythe et al. 1990) 
 
  
The mentioned criteria can shorten the diagnosis process to identify affected persons. 
However, the use of the ACR-criteria in the clinic has been criticised because Fibromyalgia 
comprises many more symptoms of varying occurrence which are not included in the 
classification criteria (Wolfe et al., 2003) (Hauser, Zimmer et al. 2008). 
Characteristically, patients report musculoskeletal pain of changing intensity. The location of 
the painful regions may change daily or even within hours. Frequently, pain begins at one site 
of the body, e.g. at the lower back or cervical spine, and then generalizes. Accordingly, the 
patient may not be able to name the main site of pain. Cold and wet weather is often described 
as an aggravating, warm weather as a relieving factor. Pain is sometimes accompanied by 
morning stiffness, perceived muscle tenderness, non restorative sleep or day-time fatigue. 
Patients may also experience a subjective swelling of muscle-associated soft tissue and joints 
(Muller and Lautenschlager 1990; Conrad 2003). Physical performance and strength are often 
reduced (Panton, Kingsley et al. 2006). Some patients report a decline in memory, cognitive 
function and mental alertness (Dick, Verrier et al. 2008; Glass 2008). Consequently, patients 
may find it very difficult to face the tasks of everyday life, and often feel limited in their 
ability to work (Henriksson, Liedberg et al. 2005). 
13 
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Concerning comorbidities, patients were found to have a higher lifetime prevalence of mood 
and anxiety disorders, e.g. major depression disorder and panic disorder (Walker, Keegan et al. 
1997) Furthermore, they are more likely to be affected by headaches, systemic lupus 
erythematosus and rheumatoid arthritis (Weir, Harlan et al. 2006). 
A high percentage of Fibromyalgia symptoms overlap with those of other so called central 
pain syndromes, for example Irritable Bowel Syndrome, Chronic Fatigue Syndrome and 
Temporomandibular Syndrome (Lund, Bengtsson et al. 1986; Aaron, Burke et al. 2000; 
Clauw and Crofford 2003; Dadabhoy and Clauw 2006). 
Important differential diagnoses are rheumatic or other systemic diseases, e.g. colitis ulcerosa, 
endocrine disturbances or malignancies. These severe illnesses can mimic Fibromyalgia and 
have to be excluded carefully (Hwang and Barkhuizen 2006). 
5.3. Aetiology 
Up to now, specialists in pain treatment, psychosomatics, rheumatology, physical and 
rehabilitation medicine and neurobiologists have not found a clear answer to the question of 
the aetiology of Fibromyalgia. 
 
A substantial number of Fibromyalgia patients meet the diagnostic criteria for psychiatric 
disorders, such as major depression disorder or bipolar disorder. Even those patients, who do 
not completely fulfil the criteria for major depression disorder, sometimes present the same 
clinical symptoms in lower intensity. Consequently, some psychiatric experts regard 
Fibromyalgia as an affective spectrum disorder (Raphael, Janal et al. 2004; Raphael, Janal et 
al. 2004).  
 
Experts in the field of developmental psychology argue that patients with somatoform 
disorder and patients with Fibromyalgia share some striking ailments. On the one hand, both 
patient groups suffer from sleep disturbances and various vegetative, cardiovascular, 
neurological and gastrointestinal complaints of unknown origin. On the other hand, childhood 
adversities were found to a similar extent in both patient groups. In comparison to healthy 
controls, patients with Fibromyalgia report more negative life events during 
childhood/adolescence and adulthood in the form of physical and psychological abuse, neglect 
and death of a parent (McBeth, Macfarlane et al. 1999; Imbierowicz and Egle 2003). Within 
the meaning of the biopsychosocial model of illness, Egle et al. hypothesize that negative 
experiences in early childhood and adulthood can lead to chronic stress in form of life-long 
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victimization. The authors deduce that this kind of stress could play an important role in the 
origin and maintenance of Fibromyalgia (Van Houdenhove, Neerinckx et al. 2001; Egle and 
van Houdenhove 2006). 
 
Neurobiologists, however, assume that alterations in central pain pathways are the reason for 
this syndrome. Beside demonstrating neuroanatomical changes (Kuchinad, Schweinhardt et al. 
2007) neuroimaging studies support the idea that amplification of pain sensitivity plays an 
important role in the pathogenesis of Fibromyalgia. In functional magnetic resonance 
tomography, for instance, painful pressure leads to the same pattern of brain activation in 
patients with Fibromyalgia and healthy controls. But the pressure force that is needed to 
evoke this specific pattern has been significantly lower in the patient group. Additionally, 
examinations with single-photon emission computer tomography show reduced blood flow in 
pain-related regions, what could also point towards altered pain processing (Bradley, 
McKendree-Smith et al. 2000; Gracely, Petzke et al. 2002; Guedj, Cammilleri et al. 2008; 
Burgmer, Pogatzki-Zahn et al. 2009). Further arguments for changes in central pain 
processing have been delivered by studies investigating the reply to repetitive painful heat and 
mechanical stimulation. Following the stimuli, patients have after-sensations with greater 
magnitude, which last longer and are more often painful than in healthy controls. This 
enhanced temporal summation of second pain (“windup”) indicates central pain amplification 
and so called central sensitization. Furthermore, Price et al. assumes that evoked or ongoing 
impulse input from deep tissue, e.g. minor pathological changes, might sensitize 
intramuscular nociceptors leading to long-term neuroplastic changes and, consequently, 
central sensitization (Price and Staud 2005). These pathological changes in deep tissues like 
muscles, for example, have been found as a low amount of intramuscular collagen, “rubber 
band” morphology and disturbed regulation of intramuscular microcirculation that causes 
hypoxia and pH changes (Lund, Bengtsson et al. 1986; Jacobsen, Bartels et al. 1991; 
Gronemann, Ribel-Madsen et al. 2004). Two other findings also indicate ongoing activity in 
afferent nociceptive nerves. First, Substance P, a neuropeptide in the central nervous system, 
has been found to be elevated in the Cerebrospinal Fluid in patients with Fibromyalgia. 
Second, skin biopsies have revealed neurogenic inflammation which is also caused by 
substance P, possibly released from the peripheral endings of primary afferent nociceptive 
nerves (Vaeroy, Helle et al. 1988; Russell, Orr et al. 1994; Kim 2007). 
 
In addition to the approaches mentioned above, the neurotransmitter system in the central 
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nervous system is also a target of investigation, because the serotonin system is involved in 
pain processing and in mood regulation. Alterations of the specific serotonin transporter have 
been observed, which seem to be related to the severity of Fibromyalgia symptoms (Bazzichi, 
Giannaccini et al. 2006). Additionally, levels of 5-hydroxy indoleactic acid, a metabolite of 
serotonin, are lower than normal concentrations in the cerebrospinal fluid. Findings from 
tryptophan depletion tests, especially in regard to an augmented expression of Interleukin 6, 
indicate a dysregulation of tryptophan and serotonin metabolism. Interleukin 6 is considered 
to mediate the interaction between the neurotransmitter and the neuroendocrine system. This 
fact is remarkable, because available evidence already suggests that the hypothalamic-pituary-
adrenal axis is disturbed in patients with Fibromyalgia (Russell, Vaeroy et al. 1992; Crofford, 
Pillemer et al. 1994; Barkhudaryan and Dunn 1999; Schwarz, Offenbaecher et al. 2002; 
Crofford, Young et al. 2004). Recent studies further indicate a disturbance of the dopamine 
response to pain (Wood, Schweinhardt et al. 2007). 
 
Recently, there is a tendency towards a more holistic approach. Analogously to psychiatric 
research, molecularbiologists are trying to find a link between psychological factors and 
neuroendocrine dysregulation, because several neuroendocrine abnormalities occur as a result 
of chronic stress and are also observed in Fibromyalgia. Gupta et al hypothesize that 
Fibromyalgia develops subsequently to chronic stress (Gupta and Silman 2004). Weissbecker 
et al describe childhood physical and sexual abuse in women with Fibromyalgia as predictors 
of flattened diurnal cortisol rhythms. Consequently, they suggest that traumatic early life 
experiences may be a factor of adult neuroendocrine dysregulation among Fibromyalgia 
patients (Weissbecker, Floyd et al. 2006). 
5.4. Treatment 
Only recently, standardized guidelines for treating this patient group have been developed. 
(Hardinghaus 2008; Klement, Hauser et al. 2008). However, in this guideline, only very few 
interventions (cognitive-behavioural therapy, aerobic exercise training and medication with 
amitriptyline and multidisciplinary interventions) show the highest level of evidence. The 
uncertainty of the effectiveness of many other interventions may be the consequence of the 
variety of symptoms and the uncertainty about aetiology. Nevertheless, maximizing health, 
functioning and independence are the primary rehabilitation aims in all therapeutic approaches.  
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A large variety of medication such as antidepressants, antiepileptic drugs, non-steroidal anti-
inflammatory drugs, opiates and sleeping aids are used in the treatment of patients with 
Fibromyalgia. Antidepressive substances are essential in the pharmacological treatment of 
Fibromyalgia (Littlejohn and Guymer 2006; Sommer, Hauser et al. 2008). The tricyclic agent 
Amitriptyline is generally the first choice for initial therapy. The dosage is normally 
prescribed lower than the dosage necessary for patients suffering from depression. 
Amitriptyline has been shown to be efficacious in improving sleep quality and decreasing 
moderate pain in 25 to 45 % of the patients. But it seems to have no effect on tenderness and 
stiffness. However, the exact mode of action is not known (Arnold, Keck et al. 2000; 
Nishishinya, Urrutia et al. 2008). 
Beside the relatively old tricyclic substances, the newer specific reuptake inhibitors have been 
seen to be effective. Interestingly, the coupled serotonin and norepinephrine reuptake 
inhibitors like Milnacipran, Duloxetine or Venlafaxine appear to be more beneficial than 
single reuptake inhibitors. The intake of these substances reduces pain in 60% of the treated 
patients. This effect seems to be independent of the effect on mood, as it appears prior to 
improvement of mood disorder (Sayar, Aksu et al. 2003; Arnold, Lu et al. 2004; Gendreau, 
Thorn et al. 2005; Lawson 2006; Littlejohn and Guymer 2006; Uceyler, Offenbacher et al. 
2008). Additionally, the selective serotonin reuptake inhibitor Fluoxetine and the selective 
norepinephrine reuptake inhibitor Reboxetine lead to alleviation of some Fibromyalgia 
specific symptoms (Arnold, Hess et al. 2002; Krell, Leuchter et al. 2005). 
Recently, Antiepileptic Drugs have come up in the treatment of chronic pain conditions. 
Actually, there is evidence that Pregabalin and Gabapentine lead not only to clinically 
meaningful improvement concerning pain relief, but also to a decrease of fatigue and 
improvement of sleep and health-related quality of life in patients with Fibromyalgia 
(Crofford, Rowbotham et al. 2005; Mease 2005; Arnold, Goldenberg et al. 2007; Lyseng-
Williamson and Siddiqui 2008). 
The original assumption of Fibromyalgia having an inflammatory background was replaced 
by the opinion that there is no tissue inflammation involved in the pathogenesis. Consistent 
with this concept, clinical studies failed to prove the effectiveness of non-steroidal anti-
inflammatory drugs and steroidal drugs like Prednisone (Goldenberg, Burckhardt et al. 2004). 
Nevertheless, patients report a modest benefit from these types of substances. This could be 
due to the reduction of painful comorbidities, e.g. tendonitis, or other peripheral tissue 
pathology that contribute to central sensitization (Dadabhoy and Clauw 2006). 
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Although Tramadol was found to reduce pain, narcotic analgesics are not generally 
recommended for the treatment of Fibromyalgia (Biasi, Manca et al. 1998; Bennett, Kamin et 
al. 2003; Goldenberg, Burckhardt et al. 2004; Bennett, Schein et al. 2005). 
Additional sleep inducing substances are often prescribed for a short time in order to deal with 
disturbed sleep patterns and resulting fatigue, e.g. the atypical benzodiazepine Zolpidem 
(Moldofsky, Lue et al. 1996). 
Apart from the more or less established medication concepts, there have been investigational 
approaches with interesting, though often limited, results for the use of the dopamine-3-
receptor antagonist Pramipexole, the specific 5HT3 antagonist Tropisetron or the injections of 
Growth Hormone (Kohnen, Farber et al. 2004; Holman and Myers 2005; Jones, Deodhar et al. 
2007). 
 
Non-pharmacological treatment is mostly applied in order to deal with the psychosocial and 
functional consequences of Fibromyalgia. The idea is to prevent the decrease of activity, 
isolation and maladaptive illness behaviours and to manage poor sleep and distress (Dadabhoy 
and Clauw 2006). 
General patient education about the nature and course of the illness has been shown to 
improve patients’ self-efficacy for managing pain. They gain greater sense of controlling their 
condition and feel less anxious and helpless (Hammond and Freeman 2006). Further 
psychological interventions, especially cognitive-behavioural therapy, are meant to positively 
influence psychosocial factors that are connected to illness behaviour, health-care seeking and 
self-management for pain, pain perception and coping skills (Williams 2003; Kashikar-Zuck, 
Swain et al. 2005; Thieme, Hauser et al. 2008). Teaching and applying relaxation techniques, 
for example Progressive Muscle Relaxation or Biofeedback training, is considered to be 
useful for managing pain and insomnia and can lead to better functioning and concentration 
(JAMA 1996 [no authors listed]; Adams and Sim 2005). In order to treat physical impairment 
and prevent inactivity, aerobic exercise training and low-dose intensity sports, e.g. slow 
walking, cycling, swimming and easy gymnastical exercise (Mannerkorpi and Iversen 2003; 
Redondo, Justo et al. 2004) are recommended. Additional physical therapy modalities, such as 
physiotherapy, massage, cryotherapy and TENS (Transcutaneous Electrical Nerve Stimulator), 
are able to contribute to reducing impairment in functioning and disease consequences 
(Offenbacher and Stucki 2000). 
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For patients with more severe limitations of functioning, multidisciplinary programs that 
include patient education, exercise, psychological interventions and physical medicine are 
recommended. This combination is likely to be able to face the symptom complexity and the 
various problems patients have to deal with (Goldenberg, Burckhardt et al. 2004; Adams and 
Sim 2005; Burckhardt 2006). Recently, due to emerging pharmacological opportunities, there 
is also a call for further trials that study the standardized use of drugs, embedded in 
multidisciplinary programs. (Forseth and Gran 2002; Arnold 2006; Arnold, Hauser et al. 
2008).  
 
However, the existing conventional treatment approaches haven’t yet brought satisfying 
results. As a consequence, complementary and alternative medicine has gained increasing 
popularity among individuals with Fibromyalgia (Pioro-Boisset, Esdaile et al. 1996; Astin, 
Berman et al. 2003; Holdcraft, Assefi et al. 2003; Gard 2005; Langhorst, Hauser et al. 2008). 
5.5. Electromyogram – Biofeedback (EMG-biofeedback) 
Since 1987, a few studies have explored the effectiveness of EMG-biofeedback in patients 
with Fibromyalgia. 
The idea of biofeedback in general is to make body parameters, of which one is normally 
unaware, observable for the client. These parameters are, for example, heart rate, blood 
pressure, skin temperature or muscle tension. The client receives the information about the 
parameter in form of sound or visualization on a screen. By help of this feedback, he or she 
can learn to gain operant control over the respective parameter. 
The target system of Electromyogram-Biofeedback is the muscle – specifically the muscle 
tension. This kind of Biofeedback training is a scientifically established technique to reduce 
stress and tenseness and can be combined with relaxation techniques. Normally, surface 
electromyogram is used. The electrodes are placed on distinct formerly chosen muscles to 
measure their activity. The results are displayed visually on a screen and/or are indicated by a 
tone. This permits the patient to see and/or hear the level of muscle tension and learn how to 
influence it consciously. EMG-biofeedback training is successfully employed in the treatment 
of migraine, chronic tension headache or chronic whiplash associated disorder. Moreover, the  
method was shown to be beneficial without having inconvenient side-effects (Bogaards and 
ter Kuile 1994; Voerman, Vollenbroek-Hutten et al. 2006; Nestoriuc and Martin 2007) . 
 
Since there are parallels in the pathology of the above-mentioned diseases and Fibromyalgia, 
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there were several attempts to transfer the beneficial effect of EMG-biofeedback to patients 
suffering from Fibromyalgia. In this context, four publications from Ferraccioli (1987), 
Buckelew (1998), Van Santen (2002) and Drexler (2002) have to be mentioned (see table 1). 
In a controlled clinical trial, the group around Ferraccioli showed that EMG-biofeedback had 
a positive effect on the Tender Point Count, morning stiffness and pain intensity. Post-hoc 
analyses indicated that patients with depression in the Minnesota Multiphasic Personality 
Inventory or with a “psychosomatic background” apparently didn’t have that benefit. 
(Ferraccioli, Ghirelli et al. 1987). 
In 1998, Buckelew et al. compared Biofeedback/Relaxation training to exercise only, the 
combination of exercise and biofeedback/relaxation and to education/attention that served as 
control. They found enhanced “self-efficacy” in all 3 treatments groups. The authors 
concluded that EMG-biofeedback training had some beneficial effect. Yet, they only found a 
statistically significant improvement in the Tender Point Index in relation to the 
education/attention group. So, it remained unclear, if EMG-biofeedback was more effective 
than the control (Buckelew, Conway et al. 1998). 
Van Santen et al. conducted a randomized controlled trial to compare EMG-biofeedback 
training to fitness training and control. The authors ascertained that they could not detect a 
greater benefit from biofeedback and fitness training than usual medical care. As possible 
reasons, they mentioned the restricted biofeedback protocol, the selected outcome measures 
and the high variability of outcome results between and within the groups (van Santen, 
Bolwijn et al. 2002). 
In the study published by Drexler et al, the 24 patients were first classed into a 
“psychologically abnormal” and a “psychologically normal” group according to their results 
in the Minnesota Multiphasic Personality Inventory. Both groups then underwent the same 
biofeedback training program. The baseline values of Pressure Point Sensitivity, Sensory and 
Affective Pain dimension and the SF-36 showed greater impairment in the “Abnormal group”. 
After treatment, both groups improved in Pressure Point Sensitivity – the “normal” more than 
the “abnormal” group - and secondary symptoms. The “abnormal group” showed more 
positive changes in generic health status and decreased Sensory and Affective Pain. The 
authors assumed that both groups benefited from EMG-biofeedback training. The findings 
raise the question as to what degree and in which way psychological background factors 
interfere with responsiveness to treatment (Drexler, Mur et al. 2002). 
 
The comparison of these four studies shows that the studies are heterogeneous, the study 
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designs and outcome measures have some weaknesses and the conclusions of the authors are 
different. Accordingly, this randomised controlled trial with the objective to evaluate the 
effectiveness of EMG-biofeedback in patients with Fibromyalgia was designed. The specific 
aim was to examine the effectiveness of EMG-biofeedback training in patients with 
Fibromyalgia by measurement of health status assessed in the Fibromyalgia Impact 
Questionnaire Total Score. Weaknesses of previous studies were addressed by performing an 
RCT with blinded assessors. Valid, reliable and international measures of outcomes relevant 
to the patient were used (Mease 2005; Mease, Arnold et al. 2007). The intervention group 
received EMG-biofeedback in addition to usual medical care, but no additional instructions of 
relaxation techniques that could mask the effect of EMG-biofeedback. 
Table 1 (Part 1): Clinical studies in the field of Fibromyalgia and EMG-biofeedback  
 
 
Author Interventions Control 
Fibromyalgia specific 
measures 
Pain Tenderness 
Ferraccioli 
et al. 
EMG-biofeedback on M. frontalis with Progressive Muscle 
Relaxation  
(N = 6) 
“false EMG-
biofeedback”  
(N = 6) 
• Morning stiffness * • VAS * • Tender Point 
Count * 
Buckelew 
et al. 
EMG-biofeedback on M. trapezius with not specified 
relaxation techniques (N = 29), exercise (N = 30) and 
Combination of EMG-biofeedback and exercise 
(N = 30) 
Education/attention 
(N = 30) 
• Sleep measure * 
• Arthritis Impact measurement 
scales (AIMS): Physical 
activity scale ** 
• VAS * 
• Pain 
behaviour 
measure * 
• Tender Point 
Index * 
• Total Myalgic 
Score ** 
Van Santen 
et al. 
EMG-biofeedback on M.frontalis with Progressive Muscle 
Relaxation(N=56) and fitness program  
(N = 58) 
Usual care  
(N=29) 
• General fatigue ** 
• Physical fitness ** 
• Arthritis Impact Measurement 
Scales – Total Score ** 
• VAS ** • Tender Point 
Count ** 
• Total Myalgic 
Score ** 
Drexler 
et al. 
EMG-biofeedback on M.frontalis with Progressive Muscle 
Relaxation(N=56) and fitness program  
(N = 58) 
No control group No measures 
 
 
 
 
• Pressure Point 
sensitivity * 
• Pain 
Perception 
Scale (*/**) 
No measures 
Table 1: Clinical studies in the field of Fibromyalgia and EMG-biofeedback, * = significant improvement, ** = no significant improvement 
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Table 1 (Part 2): Clinical studies in the field of Fibromyalgia and EMG-biofeedback  
 
Author 
General 
Health 
Mental Health 
Additional 
measures 
Outcome Comment 
Ferraccioli 
et al. 
No 
measures 
• Minnesota 
Multiphasic 
Personality Inventory 
No measures EMG-biofeedback is effective in reducing pain and the number of 
Tender Points and in improving the symptomatology 
ACR-criteria not 
available at point of 
inclusion; small sample 
size 
Buckelew 
et al. 
No 
measures 
• Symptom Checklist 
90 Revised * 
• Center for 
Epidemiologic 
studies – Depression 
Scale * 
• Physician’s 
rating of disease 
severity * 
• Self – efficacy * 
EMG-biofeedback is effective (within-group comparison) in reducing 
pain, pain behaviour and psychological distress and in improving sleep. 
Yet, improvement in between-group comparison was only observed in 
Self-efficacy. There was no effect on physical activity. 
Use of Yunus and 
ACR-criteria;  
Van Santen 
et al. 
No 
measures 
• Symptom Checklist 
90 Revised ** 
No measures EMG-biofeedback is not superior to usual care (between-group 
comparison). There were no effects on pain, psychological distress, 
physical fitness, functional ability and patients’ subjective well being.  
Four study arms; 
between-group 
comparison by 
ANOVA 
Drexler 
et al. 
• Short 
Form 36   
• Minnesota 
Multiphasic 
Personality Inventory 
No Measures EMG-biofeedback improves health related quality of life, importance of 
patients’ psychological status  
No RCT 
 
Table 1: Clinical studies in the field of Fibromyalgia and EMG-biofeedback, * = significant improvement, ** = no significant improvement 
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6. Methods 
6.1. Study Design 
This project was conceptualized as a one-centre randomized, assessor-blinded controlled trial 
with an intervention and a control group. There were three points of assessment: before 
intervention (baseline, T0), at the end of treatment (T1) and at follow-up after 3 months (T2) 
(figure 2, p).  
The study was approved by the ethical committee of the Ludwig-Maximilians-University 
Munich, Germany. 
The study design is shown in figure 2 (p.26).  
6.2. Setting 
The study was conducted in the outpatient clinic of the department of Physical Medicine and 
rehabilitation at the Ludwig-Maximilians-University Munich, Germany.  
6.3. Patient recruitment and data collection procedure 
Patients were recruited from the waiting list of the Fibromyalgia day hospital program of the 
department of Physical Medicine and Rehabilitation. In this context, the diagnosis was 
confirmed in accordance to the ACR-criteria and the criteria of Müller and Lautenschläger 
(Muller and Lautenschlager 1990; Wolfe, Smythe et al. 1990). 
The recruitment process of our study started with the invitation of patients to the baseline visit 
(T0) of the study. A specialist in Physical Medicine and Rehabilitation asked for the medical 
history of the patient and performed a general examination including body height, weight, 
blood pressure and heart rate. Then, the Tender Points defined by the ACR-criteria and 
control points were palpated (Okifuji, Turk et al. 1997). The 3 pairs of control points were 
located at the humeral-radial joint, in the dorsal soft tissue between ulna and radius in the 
transition zone between medial and distal forearm and in the soft tissue between first and 
second beam of the hypothenar. 
Patients were finally included in the EMG-biofeedback study, if they were female, between 
18 and 65 years old, had the cognitive ability and sufficient German language skills to fill in 
the questionnaires and signed the provided informed consent. Exclusion criteria were major 
medical disorders, i.e. cancer, chronic heart failure NYHA IV or asthma requiring cortisone 
medication, suffering from psychosis or major affective disorders, substance abuse, co-
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medication with opiates or benzodiazepine, transmeridian flight in the last weeks or shift-
work or gravity.  
Patients who fulfilled the inclusion criteria and who had no exclusion criteria were asked to 
fill in the informed consent. The patient then received the first set of questionnaires and was 
randomized to the treatment or control group.  
Patients were randomized by a block randomization of two or four to the treatment or control 
group. Block sizes were determined by a random fashion. Random numbers were generated 
by the Microsoft EXCEL program. A person who was neither involved in the intervention nor 
in the assessments provided sealed envelopes with the group assignments.  
Within three days after inclusion, the patient was presented to a specialist in psychosomatic 
medicine for additional evaluation. After that the first meeting with the Biofeedback therapist 
took place. To avoid bias in the psychosomatic evaluation, patients were not informed about 
their group allocation prior to the first visit.  
Intervention patients proceeded to perform 14 sessions of EMG-biofeedback training 
according to the study protocol (see 6.4). During the first three weeks, they had three 
appointments per week and one appointment per week during the following five weeks.  
With an interval of 8 weeks, the control group had only two encounters with the therapist. 
During the observation period, all patients in both groups received the usual medical care. 
This included the temporary intake of acetaminophen for acute pain, which patients were 
asked to record in a diary. Additionally, they were asked not to begin any other treatment for 
Fibromyalgia during the study. 
The intervention group was given the second set of questionnaires at the end of the 14th 
training session, the control group at the second appointment with the therapist.  
Before undergoing the second clinical examination at the end of treatment (T1), all patients 
were instructed not to mention to which group they belonged in presence of the examiner.  
After 12 weeks (T2), the third set of questionnaires was sent to all patients. 
  
 Physical examination & Psychosomatic evaluation T0 
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Randomization 
 
 Intervention group: 1st EMG-
Biofeedback session 
Control group: 1st EMG-
Biofeedback session  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Study design, T0 = baseline, T1 = end of treatment, T2 = 3-months follow-up 
T1 
T2 
Intervention group: 14th EMG-
Biofeedback session 
Control group: 2nd EMG-
Biofeedback session 
Physical examination 
Week 1 – 3: 3 sessions/week  
+ usual medical care 
Week 1 - 8: usual medical care 
Week 4 - 8: 1 session/week 
+ usual medical care 
3-months follow-up 
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6.4. Technical aspects and Biofeedback training protocol 
The biofeedback training was performed with the Schuhfried Biofeedback apparatus and 
software “Biofeedback 2000 x-pert”, all provided by Schwa-medico, Ehringshausen, 
Germany. 
At the beginning of each treatment session, patients were asked to assess pain, nervousness, 
depressive mood, fatigue, and stiffness on a visual analogue scale. Then, the Biofeedback 
apparatus’ electrodes were placed on both the upper and lower trapezius muscle; the grounded 
electrode was placed on the medial part of the upper trapezius muscle. The apparatus 
displayed one EMG curve for each side on a computer screen, which visualized the muscle 
tension. First, the EMG activity of the trapezius muscle was measured for 5 minutes in order 
to get a solid baseline. The intervention patients were instructed that an ascending curve 
corresponded to increasing and a descending curve to decreasing muscle tension. There was 
no instruction about specific relaxation techniques. After that, the task of the patient was to 
consciously strain the trapezius muscles for 3 minutes. In the following 10 minutes the 
patients were asked to relax these muscles. During the entire duration of muscle straining and 
relaxation, they received visual feedback of muscle tension in form of EMG curves. The 
procedure of conscious muscle straining and relaxation was done twice. After each cycle, the 
self-assessment with visual analogue scales was repeated as in the beginning. At the end of 
the training session, these results and the patients’ feeling of muscle tension were discussed in 
relation to the EMG-biofeedback curves. Finally, patients were encouraged to do a home 
exercise program, in which they consciously relaxed the muscle by using “their” relaxation 
technique analogously to the biofeedback session for about 15 minutes per day. Additionally, 
they should try to apply the techniques in stressful situations, for example appointments at the 
dentist’s. 
The patients in the control group, however, had two encounters with the therapist, where they 
assessed visual analogue scales and their trapezius muscle activity was measured during 5 
minutes, just as in the intervention group. But afterwards, they did not continue with muscle 
straining and relaxation.  
6.5. Measures 
In this study, data was collected at three time-points. Table 2 displays the measures and their 
application at each assessment.  
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Measure Baseline (T0) 
End of 
treatment (T1) 
3 – months – 
follow-up 
Outcome 
domaines 
Sociodemography X -- -- 
Sociodemographic 
data 
SCQ X -- -- Comorbidities 
FIQ X X X Disease specific 
Tender Point 
Score 
X X X Self-reported pain 
Dolorimetry X X -- 
Tenderness, Pain 
Pressure 
Threshold 
Tender Point 
Count (number of 
Tender Points) 
X X -- 
Tenderness, 
widespread pain 
SF - 36 X X X 
Generic health 
status 
Patients’ Global 
Clinical 
Impression of 
Change 
-- X X Change of health 
BDI X X X Depression 
SCL90-R X -- X 
Psychological 
distress 
Table 2: Measures 
Legend to table 2: SCQ = Self–administered Comorbidity Questionnaire, FIQ = Fibromyalgia Impact 
Questionnaire, SF – 36 = Short Form 36, BDI = Beck Depression Inventory, SCL90-R = Symptom Checklist 90 
Revised 
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6.5.1. Measures of sociodemography and comorbidities 
Sociodemographic characteristics were assessed by a questionnaire asking for first language, 
education, status of employment, working hours per week, smoking, alcohol consumption and 
physical activity. 
Further, patients were asked for the date of onset of Fibromyalgia symptoms. 
Comorbidities were evaluated using the Self-administered Comorbidity Questionnaire. It asks 
for the presence of a number of health problems, for example heart disease or back pain. For 
each problem the questionnaire has the option to ask “Do you receive treatment for it?” and 
“Does it limit your activities?” as proxies for disease severity and the burden of disease. In the 
present German version, there are 13 medical problems and three optional conditions. The 
maximum score is 3 points for each problem/condition. The total maximum score is 39 points, 
if only the defined items are included, or 48 points, if the optional items are included. (Sangha, 
Stucki et al. 2003). 
6.5.2. Primary outcome measure 
The Fibromyalgia Impact Questionnaire is a disease specific multidimensional measure of 
patient status, progress and outcomes. It is considered to capture the global effect of 
Fibromyalgia symptomatology, and covers the dimensions physical functioning (11 items), 
well-being (1 item), work situation (2 items), pain (1 item), fatigue /sleep (2 items), stiffness 
(2 items) and psychological symptoms (2 items). It is extensively used and has shown good 
responsiveness to change in clinical studies. Scoring ranges from 0 to 80 with the latter 
number being the worst case. Specifically, the Fibromyalgia Impact Questionnaire Total Score 
gives a summary of patients’ impairment and is recommended as a highly sensitive measure 
of change in Fibromyalgia treatment programs and clinical studies (Burckhardt, Clark et al. 
1991; Dunkl, Taylor et al. 2000; Maura Daly 2003; Bennett 2005). There are translations in 
different languages available. In this study the German validated version was used 
(Offenbaecher, Waltz et al. 2000). 
6.5.3. Secondary outcome measures 
Pain measures comprise instruments for self-report pain and tenderness.  
The Tender Point Score consists of a body diagram, where patients can rate the pain intensity 
at 24 locations of the front and the back side of the body that are commonly indicated as 
painful by Fibromyalgia patients. It allows calculating a total score for the whole body, as 
well as specific local scores (Lautenschlager, Seglias et al. 1991). 
According to the Tender point manual survey, the Tender Point Count was assessed by thumb 
palpation. The examiner applied discrete pressure of 4 kg/cm² to each of the 18 Fibromyalgia 
typical Tender Points. When the patients expressed pain, the tender point was considered 
positive. 
For measuring the Pressure Pain Threshold, the assessor first searched for an induration with 
pressure pain in the M trapezius pars descendens on each side of the muscle. The palpated 
part of the muscle was always located above or on a line between the acromioclavicular joint 
and the spinous process of vertebrae C 7. These two structures also served as coordinates to 
write down the exact place of the palpated taut band. Second, using a Fischer dolorimeter 
(figure 3) with a stamp of 1 cm², the examiner applied vertical pressure to the selected point 
and successively augmented the pressure until the patient signalled pain. In this way, the 
pressure pain threshold was measured in kg/cm² (Fischer 1987; Nussbaum and Downes 1998). 
 
 
Figure 3: Fischer dolorimeter 
 
The generic health status was measured by the German version of the Short-Form 36 (SF-36), 
a generic, multi-purpose, short-form health survey containing 36 questions to assess different 
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aspects of health status. It yields an eight-scale profile of scores which are Physical 
Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-
Emotional and Mental Health. This questionnaire has been proven to be useful in comparing 
general and specific populations, estimating the relative burden of different diseases, 
differentiating the health benefits resulting from a wide range of different treatments, and 
screening individual patients. (Ware and Sherbourne 1992; Bullinger 1995; Ware and Gandek 
1998). 
The self rated Patients’ Global Clinical Impression of Change Score was applied, which is a 
validated measure of overall change compared with study onset, including six possible scores 
from "very much worse" (score 1) to "very much better" (score 6) (Guy 1976). 
 
Depression was assessed by the Beck Depression Inventory (BDI). This is a questionnaire 
developed and validated for patients with depression and has been applied in clinical trials of 
patients with Fibromyalgia. It contains 21 items that assess the cognitive, affective and 
neurovegetative factors associated with depression (Beck, Ward et al. 1961; Hautzinger 1991). 
 
Further, the Symptom Checklist 90 Revised (SCL-90-R) was used, which generates 9 specific 
scales, one additional unspecific scale and three general scores. The 9 dimensions of the scale 
are as follows: SCL 1 = somatization; SCL 2 = obsessive-compulsive symptoms; SCL 3 = 
interpersonal sensitivity; SCL 4 = depression; SCL 5 = anxiety; SCL 6 = hostility; SCL 7 = 
phobic anxiety; SCL 8 = paranoid ideation; SCL 9 = psychoticism. The Global Severity Index 
serves as a measure of psychological distress (Derogatis, Lipman et al. 1973; Franke 1995). 
6.6. Analyses 
6.6.1.  Sample size calculation 
The sample size calculation was based on the hypothesis that EMG-biofeedback may have a 
similar effect as a cognitive behavioural approach, shown in a randomized clinical trail 
(Redondo, Justo et al. 2004). The analysis to determine the sample size was performed with 
the formula 2N = 4(Zα + Zβ)² σ² / δ². 
From the assumption of a power (1-ß) of 0.9, a level of significance (α) of 0.05, a reduction of 
the Fibromyalgia Impact Questionnaire by 12.8 points (SD 11.4), a sample size of 17 patients 
per treatment arm was necessary in order to detect a statistically significant difference. If the 
dropout rate up to T1 had been 10 %, a total sample size of 38 patients would have been 
necessary (Redondo, Justo et al. 2004). 
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6.6.2. Scoring of questionnaires  
The Fibromyalgia Impact Questionnaire Total Score was obtained according to the validation 
of the German 8-item version. The physical function items are rated on a 4-point Likert type 
scale; the well being and the first work related question ask the patient to mark the number of 
days they felt well and the number of days they were unable to work (including housework) in 
the last week .The other items are rated on visual analogue scales. Each item has a maximum 
possible score of 10. The Total score was calculated by adding the physical functioning score, 
numbers of days felt well, pain, fatigue, morning tiredness, stiffness, anxiety and depression. 
The highest possible score is 80 what indicates maximum impact of disease (Offenbaecher, 
Waltz et al. 2000). 
 
In the body diagram of the Tender Point Score, patients rated pain with 6-point Likert scales 
from 0 = no pain to 5 = maximal pain. All ratings of the 24 locations were added leading to a 
total score for general pain, which is maximum 120. In addition, local pain in the M. 
Trapezius region was assessed (Lautenschlager, Seglias et al. 1991). 
Concerning tenderness measures, the Tender Point Count was performed according to ACR-
criteria (Wolfe, Smythe et al. 1990). Further, we calculated the mean of the Pain Pressure 
Threshold of both sides of the M. Trapezius in order to compare the change over time.  
 
Following the SF-36 Health Survey Manual and Interpretation Guide, patients’ questionnaires 
were only included for calculation, if each scale of the SF-36 had at least 50% of the 
corresponding items answered. Each scale ranges from 0 indicating ‘maximal 
symptoms/maximal limitations/poor health’ to 100 indicating no ‘symptoms/no 
limitations/excellent health’ (Bullinger 1998).  
 
The mean of the patient ratings was calculated for the Patients’ Global Clinical Impression of 
Change (Guy 1976). 
 
The sum score of the Beck Depression Inventory was obtained as recommended in the 
handbook for the German version. The range of score is from 0 to 63, where values above 11 
indicate presence of mild to moderate depressive symptoms, and values above 18 indicate 
clinically relevant depression (Hautzinger 1995). 
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The items of the Symptom Checklist 90 Revised scales are rated on a 5–point Likert scale (O 
= not at all – 4 = very strong). In concordance with SCL-90-R manual the GSI is calculable in 
all questionnaires in the following fashion: 
GSI = GS/ (90 – number of missing items) 
GS = sum score of all answered items.  
The resulting scores are transformed to “t-values” by help of standard lists in the manual. “T-
values” between 60 and 70 indicate a distinct, 70 and above a high burden of psychological 
distress. The maximum score is 80 (Franke 1995). 
6.6.3.  Group comparison 
The null hypothesis (H0) for the primary outcome was that there is no difference of the 
changes of the FIQ Total Score between treatment and control group at T2 (Change score: T2-
T0). Analogously, H0 for secondary outcome measures were no differences of the changes at 
T1 (T1-T0) and T2 (T2-T0).  
 
In order to examine the statistical significance between the score changes, the data were tested 
on normality with the help of histograms and the comparison of means and medians. In case 
of normal distribution the t-test for independent samples was used, otherwise, the Mann-
Whitney U test for significance was performed.  
The group comparisons for secondary outcome measures were performed analogously. 
 
Additionally, effect sizes (ES) were calculated by Cohen’s d at the end of treatment and at the 
3-months follow-up.  
d is defined as the difference of two means divided through the pooled standard deviation 
(Rosenthal 1994). 
d = M1 - M2 / σpooled 
σpooled = √[(σ1²+ σ2²) / 2] 
M1 = change of mean intervention group (IC), M2 = change of mean control group (CG), σ1 = standard 
deviation intervention group, σ2 = standard deviation control group 
Cohen considered an effect size of 0.2 as a small, of 0.5 as a medium and 0.8 as a large 
positive effect of therapy. Positive effect sizes indicate an advance for the treatment groups 
(Cohen 1988). 
All data analyses were performed by using SPSS for windows, version 14.0. Outcome scores 
are illustrated by simple graphs. 
7. Results 
7.1. Patients 
Between April 2005 and April 2006, 40 female patients were enrolled in the study.  
In the intervention group as well as in the control group, one patient withdrew for private 
reasons before end of treatment. Also in the follow-up (T2), there were two drop-outs, one 
person in each group. Both patients did not return the set of questionnaires and could not be 
contacted despite several attempts. 
Finally, 36 out of 40 patients completed the study (90%).  
 
 
T2
Physial examination
Psychosomatic/Psychiatric evaluation
N = 40
Intervention group
N=20
Control goup
N=20
T0
T1N=19
N=18
N=19
N=18
Randomization
 
  Figure 4: Patients, T0 = Baseline, T1 = end of intervention, T2 = 3-months follow-up 
7.2. Patients characteristics 
7.2.1. Sociodemography 
Sociodemographic characteristics are presented in table 3. Regarding age, marital status and 
alcohol consummation there were no differences between the intervention and the control 
group. Further, the groups did not differ statistically significant in education status, smoking 
habits and physical activity (p–values not presented). 
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Intervention group 
N=18 
Control group 
N=18 
Age, mean yrs (SD) 55.4 (6.07) 55.97 (6.14) 
Mother tongue German  94.4% 100.0% 
School Education level    
Basic level (9 yrs) 38.9% 16.7% 
Middle level (10 yrs) 33.3% 61.1% 
Higher level (10-13 yrs) 27.8% 22.2% 
Marital Status    
Unmarried 22.2% 11.1% 
Married 55.6% 61.1% 
Divorced 22.2% 16.7% 
Widowed 0.0% 11.1% 
Smoking  5.6% 22.2% 
Alcohol consommation    
None 22.2% 22.2% 
Occasionally 55.6% 55.6% 
1x/d 22.2% 16.7% 
Several times/d 0.0% 11.1% 
Daily physical activity    
None 5.6% 5.6% 
< 30 min/d 44.4% 22.2% 
30 to 60 min/d 38.9% 50.0% 
> 60 min/d 11.1% 22.2% 
Weekly sporting activity    
> 2 hours/w 27.8% 50.0% 
1 to 2 hours/w 50.0% 38.9% 
< 1 hour/w 5.6% 11.1% 
None 16.7% 0.0% 
  Table 3: Sociodemography 
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7.2.2. Clinical data at baseline  
Table 4 summarizes the results of the outcome measures at baseline. In the Fibromyalgia 
Impact Questionnaire Total Score and most other measures there was no statistical group 
difference. Only the Vitality and the Role-Emotional scale of the Short-Form 36 were 
significantly better in the control group.  
 
Intervention group (N=18) 
 
Mean (SD) 
Control group (N=18) 
Mean (SD) 
p-value 
Years of complaints, mean yrs (SD)  12.44 (12.24) [range 1-43] 16.39 (9.06) [range 2-38] 0.28 
Comorbidities, mean (SD) 5.5 (4.03) 5.83 (2.6) 0.46 
FIQ Total Score 42.59 (9.71) 40.44 (14.21) 0.60 
Tender Point Score    
Total Score 55.97 (18.62) 58.82 (20.34) 0.66 
Trapezius Score 3.08 (1.10) 3.56 (0.92) 0.17 
Tender Point Count, mean (SD) 15.95 (1.51) 16.32 (1.67) 0.33 
Dolorimetry (kg/cm²) 1.55 (0.70)3 1.63 (0.65)3 0.71 
SF-36    
Physical functioning 47.62 (13.42)1 54.17 (19.19) 0.25 
Role-Physical 26.56 (34.72)2 38.89 (39.50) 0.36 
Bodily Pain 38.59 (10.65)1 36.94 (12.49) 0.68 
General Health 37.94 (18.88)1 41.83 (14.35) 0.50 
Vitality 26.76 (17.32)1 37.22 (12.86) 0.05* 
Social functioning 53.68 (24.91)1 60.42 (23.58) 0.40 
Role-Emotional 25.00 (35.49)2 57.41 (43.99) 0.04* 
Mental Health 50.82 (15.48)1 57.28 (16.77) 0.25 
BDI, mean (SD) 17.55 (8.16) 12.77 (6.36) 0.06 
SCL90-R    
Global Severity Index, mean (SD) 66.89 (11.29) 60.83 (13.60) 0.16 
  Table 4: Baseline characteristics of Fibromyalgia patients (N=36) 
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Legend to table 4: 
SD = standard deviation (written in parenthesis), 1 N = 17, 2 N = 16, 3 N = 19 
FIQ (= Fibromyalgia Impact Questionnaire) Total Score scale: 0 = best health status, 80 = worst health status, Tender Point Score Total Score Scale 
0 = no pain, 100 = maximal pain, Trapezius Score scale 0 = no pain, 5 = maximal pain, Dolorimetry = applied pressure in kg/cm², SF-36 scale 0 = 
worst health, 100 = best health, BDI ( = Beck Depression Inventory) scale 0 – 11 = no depression, 12 – 18 = depressive symptoms, 19 – 63 = 
clinical meaningful depression, SCL90-R (Symptom Checklist 90 Revised) Global Severity Index scale: 60 - 70 = moderate psychological distress,  
> 70 = high burden of psychological distress. 
Tests for significance: Number of Tender Points, Role-Physical, Social Functioning, Role-Emotional: Mann – Whitney U – test; All other 
scales: t - test for independent samples.   
* = statistically significant difference 
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7.2.3. Primary and secondary outcome measures 
The primary outcome, the Fibromyalgia Impact Questionnaire Total Score, and all secondary 
outcome measures, including the Tender Point Score, the Tender Point Count and the 
Pressure Pain Threshold, the SF-36 and Patients’ Global Clinical Impression of Change, the 
Beck Depression Inventory and the Global Severity Index of the SCL-90-R are shown in table 
5. Figure 5 shows the course of the Fibromyalgia Impact Questionnaire Total Score for both 
groups.  
 
There was no difference in the changes of the FIQ Total Score between the intervention and 
the control group at the end of treatment (ES = 0.02, p = 0.95). Their scores improved by the 
same degree. Also at the follow-up there were no group differences, even though the 
intervention group maintained approximately the same level and the controls´ score increased 
(ES = 0.26, p = 0.43).   
 
With only one exception, there were also no statistically significant differences in the changes 
of the secondary outcome measures between the groups. Only the Pain Pressure Threshold at 
the end of treatment was significantly higher in the intervention group (ES = 0.26, p = 0.014).  
 
Table 5: Outcome of Fibromyalgia patients from baseline to 3-months follow–up (N = 36) 
Baseline (T0) T1 T2 
Intervention 
group (N18) 
Control group 
(N18) 
Intervention 
group (N18) 
Control group 
(N18) 
Comparison 
of changes  
Intervention group 
(N18) 
Control group 
(N18) 
Comparison 
of changes 
 
Mean (SD) Mean (SD) Mean (SD) Mean (SD) (p-value /ES4) Mean (SD) Mean (SD) 
(p-value 
/ES4) 
FIQ         
Total Score 42.59 (9.71) 40.44 (14.21) 37.11 (14.89) 35.23 (17.16) 0.95/0.02 37.87 (9.65) 38.28 (15.58) 0.43/0.26 
Tender Point 
Score         
Total Score 55.97 (18.62) 58.82 (20.34) 54.56 (19.13) 63.44 (21.76) 0.37/0.45 53.00 (20.69) 58.94 (16.54) 0.44/0.22 
Trapezius Score 3.08 (1.10) 3.56 (0.92) 2.94 (1.20) 3.31 (0.88) 0.73/-0.12 3.08 (1.27) 3.17 (1.06) 0.25/-0.39 
Tender Point 
Count 15.95 (1.51) 16.32 (1.67) 14.74 (1.91) 15.68 (2.29) 0.402/0.3    
Dolorimetry 1.55 (0.70)3 1.63 (0.65)3 2.08 (0.94)3 1.72 (0. 74)3 0.014*/0.84    
SF-36         
Physical 
functioning 47.62 (13.42)
1 54.17 (19.19) 49.31(19.41)1 54.23 (24.34) 0.67/0.14 51.64 (21.01)1 51.64 (21.01) 0.21/0.43 
Role-Physical 26.56 (34.72)2 38.89 (39.50) 14.06 (27.34)2 33.33 (38.35) 0.47/-0.21 15.62 (25.62)2 20.83 (32.37) 0.57/0.25 
Bodily Pain 38.59 (10.65)1 36.94 (12.49) 36.71(16.00)1 30.44 (16.92) 0.43/0.27 36.88 (11.52)1 36.17 (15.34) 0.84/-0.07 
General Health 37.94 (18.88)1 41.83 (14.35) 36.53 (19.21)1 44.67 (18.53) 0.14/-0.52 43.50 (16.50)1 44.44 (18.33) 0.47/0.24 
Vitality 26.76 (17.32)1 37.22 (12.86) 28.24 (17.58)1 41.67 (14.85) 0.52/-0.22 28.63 (16.35)1 38.80 (15.49) 0.94/0.03 
Social 
functioning 53.68 (24.91)
1 60.42 (23.58) 50.00 (22.10)1 60.42 (27.20) 0.61/-0.14 53.68 (25.68)1 61.11 (25.69) 0.86/-0.03 
Role-Emotional 25.00 (35.49)2 57.41 (43.99) 47.92 (47.09)2 57.41 (43.99) 0.16/0.54 35.42 (42.98)2 59.26 (47.90) 0.77/0.2 
Mental Health 50.82 (15.48)1 57.28 (16.77) 51.35 (20.14)1 60.67 (21.49) 0.53/-0.21 51.06 (17. 86)1 57.50 (18.36) 1.00/0 
Global clinical 
impression   3.37( 0 60) 3.00 (0. 67) 0.08/0.58 3.17 (0.62) 2.78 (1.00) 0.17/0.47 
BDI 17.55 (8.16) 12.77 (6.36) 16.11 (8.78) 12.89 (7.3) 0.44/0.26 16.91 (8.33) 12.30 (6.31) 0.93/-0.03 
SCL90-R         
Global Severity 
Index 66.89 (11.29) 60.83 (13.60)    66.11 (11.28) 63.22 (12.75) 0.12/0.53 
 40
 41 
Legend to table 5: 
SD = standard deviation (written in parenthesis), 1 N = 17, 2 N = 16, 3 N = 19 
FIQ (= Fibromyalgia Impact Questionnaire) Total Score scale: 0 = best health status, 80 = worst health status, Tender Point Score Total Score Scale 
0 = no pain, 100 = maximal pain, Trapezius Score scale 0 = no pain, 5 = maximal pain, Dolorimetry = applied pressure in kg/cm², SF-36 scale 0 = 
worst health, 100 = best health, Clinical global impression scale 1 =  “very much worse”, 5 = “very much better”, BDI ( = Beck Depression 
Inventory) scale 0 – 11 = no depression, 12 – 18 = depressive symptoms, 19 – 63 = clinical meaningful depression, SCL90-R (Symptom Checklist 
90 Revised) Global Severity Index scale: 60 -70 = moderate psychological distress,  > 70 = high burden of psychological distress. 
ES = effect size = 4(score at end of treatment – score at baseline) / standard deviation at baseline and 5(score at 3-months follow-up – score at 
baseline) / standard deviation at baseline. 
Tests for significance: Number of Tender Points, Tender Point Score Total Score, Role-Physical, Social Functioning, Role-Emotional: Mann – 
Whitney U – test; All other scales: t - test for independent samples.   
Null hypotheses: difference (mean at end of treatment - mean at baseline) = zero and difference (mean at 3-months follow-up - mean at 
baseline) = zero; p > 0.05: we accept the null hypothesis at type I error = 5%.    
* = statistically significant difference 
 
 
 Figure 5: Time course of the FIQ Total Score. 
0 = best health status, 80 = worst health status 
Baseline End of 
treatment
Follow up
30,00
32,50
35,00
37,50
40,00
42,50
45,00
Time Cour e of the FIQ Total Score
Intervention 
Group
Control Group
M
ea
n 
FI
Q
 T
ot
al
 S
co
re
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Time course of the FIQ Total Score. 0 = best health status, 80 = worst health status 
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8. Discussion 
In this randomized controlled trial EMG-biofeedback did not improve health status of patients 
with Fibromyalgia. The primary outcome measure (FIQ) and all secondary outcome measures, 
with the exception of the pressure pain threshold in the trapezius muscle, showed no 
superiority of EMG-biofeedback in addition to usual care compared to usual care alone. 
 
The four previous clinical studies that investigated EMG-biofeedback in the treatment of 
Fibromyalgia used very different outcome measures and EMG-biofeedback protocols (see 
table 1, p.19/20). In the following the comparison of this study to the previous ones is 
structured by the measured outcomes. 
In this RCT, the primary outcome was measured by the disease specific health status measure 
Fibromyalgia Impact Questionnaire Total Score. Ferraccioli at al. (1987), Buckelew et al. 
(1998) and Van Santen et al. (2002), used also disease specific patient-orientated measures 
(see table 1). In the study of Buckelew et al. “physical activity” was measured by the Arthritis 
Impact Questionnaire measurement scales (AIMS). The AIMS had served as a model to 
develop the Fibromyalgia Impact Questionnaire. In consistence with this trial Buckelew did 
not detect improvements in the disease specific health status measured by the AIMS. Likewise, 
Van Santen found no improvement in the AIMS. In contrast, Ferraccioli found significant 
improvements in “Morning stiffness” and “day-time fatigue”, domains that are included in the 
corresponding FIQ subscales. However, the positive effect cannot be clearly related to 
biofeedback, because patients in that study were taught Progressive Muscle Relaxation for use 
during the biofeedback sessions. 
 In this study, self-reported pain – throughout the body and locally – did not decrease 
significantly. Consequently, the assumption that it might be possible to achieve local and 
general pain relief by reduction of muscle tension was not confirmed. However, we found a 
positive effect in the clinical test of tenderness. The Pressure Pain Threshold increased 
significantly in the target area (ES = 0.84). In contrast, there was no significant change in the 
number of Tender Points (ES = 0.30). 
 The disconnection of self-reported pain and tenderness is consistent with results from 
Buckelew et al. (1998). But in contrast to our study, Buckelew et al. found a significant 
improvement, but not in the pressure pain threshold measured by dolorimetry (Total Myalgic 
Score). However, the pain relief in that study was only significant in within-group, but not in 
between-group comparison. In the study of Van Santen et al. (2002), there was no change, 
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neither in self reported pain (Hassett, Radvanski et al.) nor in tenderness (Total Myalgic 
Score), whereas Ferraccioli et al. observed important pain relief (Hassett, Radvanski et al.). 
Drexler et al. assessed the pain quality and could not detect significant changes in the sensory 
and affective dimensions of pain (Ferraccioli, Ghirelli et al. 1987; Buckelew, Conway et al. 
1998; Drexler, Mur et al. 2002; van Santen, Bolwijn et al. 2002). 
Generic health status was assessed by the SF-36. At baseline, the study sample 
differed significantly in the SF-36 subscales for “Vitality” and “Role-Emotional”. Whereas 
the difference in “Vitality” was maintained at the end of treatment, the intervention group 
showed fewer restrictions in facing daily tasks due to emotional problems (ES = 0.54). 
However, the total of the changes of the SF-36 subscales showed no clear tendency for a 
benefit of EMG biofeedback. This is in contrast with the results of Drexler et al. who had 
found beneficial effects in health status after biofeedback training. The authors emphasized 
that the degree of benefit depended on the Minnesota Multiphasic Personality Inventory 
profile of their clients. The “psychologically normal” group showed statistically significant 
improvements only in “Vitality” and “Mental Health”; in contrast, the “abnormal” group 
improved in all subscales, except “Role Emotional”. The study is limited, because a 
comparison with a control group was not performed. But it points out that patients’ 
psychological profiles may influence response to treatment and self-perception of health status. 
This supports the opinion that subgroups of Fibromyalgia exist and that these require different 
kinds of treatments adapted to their needs (Turk, Okifuji et al. 1998; Drexler, Mur et al. 2002; 
Giesecke, Williams et al. 2003; Muller, Schneider et al. 2007). 
 
The possible improvement in mental condition due to treatment was a topic in the 
present study and in the studies of Buckelew and Van Santen. The assessment instruments 
were similar. 
The Beck Depression Inventory showed no statistically significant improvement in the 
intergroup comparison, neither at the end of treatment nor in the follow-up. Also, the effect 
sizes were small. This corresponds with the findings of Buckelew et al., who had employed 
the Center for epidemiologic studies – Depression scale, which covers 20 items to measure 
depressive symptoms. In that study only the within-group comparison showed significant 
improvement. With respect to the Global Severity Index of the SCL-90R, that reflects the 
burden of symptomatology, our control group scored higher at the end of the observation 
period, which suggests more psychological distress, whereas the intervention group remained 
stable. The effect size reflected a moderate benefit (ES = 0.56), but the result was not 
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significant. This finding is consistent with the study of Van Santen et al. and the between-
group comparison of Buckelew et al.. The latter study group found an improvement in the 
Global Severity Index only in the pre-post comparison within the treatment group.  
Due to the inconsistent outcome of the BDI and the SCL-90-R Global Severity Index, one 
cannot conclude that the intervention may lead to a certain stabilization of mood regarding the 
burden of psychological distress. Drexler et al. treated the aspect of mental health in a 
different way. They followed the idea of Ferraccioli who postulated that patients respond 
different to treatment depending on their profile in the Minnesota Multiphasic Personality 
Inventory. So, rather than investigating if EMG-biofeedback improved patients’ mental 
condition, Drexler’s group examined the association between patients’ mental condition and 
the outcome of EMG-biofeedback training. 
 
When asked for their Global Clinical Impression of Change, patients undergoing 
EMG-biofeedback training reported that they felt a tendency toward improvement of their 
condition. In contrast, the controls announced slight worsening. The statistics revealed a 
moderate clinical effect (T1: ES = 0.58, p = 0.081, T2: ES = 0.47, p = 0.171), but this was not 
significant. The patients’ expectation in the intervention group that they underwent a potential 
beneficial treatment may have influenced the result of the global impression scale. 
 
One important question in the comparison of EMG-biofeedback studies is whether 
differences in the combinations of EMG-biofeedback and instructions to relaxation strategies 
may result in different outcomes. In the last decades it has been found that relaxation training 
alone has a beneficial effect in the treatment of chronic pain. Different relaxation techniques 
have been studied and are recommended for the treatment of Fibromyalgia (JAMA 1996 [no 
authors listed]; Holdcraft, Assefi et al. 2003; Williams 2003; Castel, Perez et al. 2007). 
In this study, EMG-biofeedback was purposely not combined with techniques, such as 
Progressive muscle relaxation of Jacobsen, autogenic training or breathing relaxation. The 
goal was to mediate relaxation solely through visual feedback of muscle tension and not with 
a specific technique supported by EMG-biofeedback. That means that we differentiated 
between biofeedback relaxation training and biofeedback-assisted relaxation. Contrarily, Van 
Santen et al. taught Progressive muscle relaxation in order to use it during EMG-biofeedback 
training. In the same fashion, Buckelew et al. proceeded with instruction of “cognitive and 
muscular relaxation strategies”. In the end, the two groups came to opposite conclusions of 
the effectiveness of EMG-biofeedback training what could be due to the different relaxation 
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strategies. Similar to the present study, Drexler et al. do not mention having employed a 
special relaxation strategy during the EMG-biofeedback training. However, that study showed 
positive effects of EMG-biofeedback. The reason might be found in the realisation of EMG-
biofeedback training itself. Unlike us, for example, Drexler et al. used acoustic feedback in 
addition to visual feedback of muscle tension. This may have lead to a more pronounced 
feedback and finally to a more beneficial effect. 
 
In this RCT we selected outcome measures that cover symptoms, problems in body 
functions and limitations in activities that are most relevant from the patients’ perspective and 
that were appropriate for the aims of the project. Specifically, the Fibromyalgia Impact 
Questionnaire Total Score was selected as primary outcome measure, because it covers 
impairments of high relevance for patients with Fibromyalgia, and it has been found to be 
sensitive to changes in the health status of patients in Fibromyalgia treatment programs and in 
clinical trials. The questionnaire was exclusively developed for Fibromyalgia and measures 
the components of health status that are believed to be mostly affected in Fibromyalgia. 
(Dunkl, Taylor et al. 2000; Maura Daly 2003; Bennett 2005). The Fibromyalgia Impact 
Questionnaire is criticized, because it was primarily validated for women and tends not to 
detect changes in patients with low levels of disability. In this study, participants were all 
female and had FIQ baseline values as high as in other trials (Offenbaecher, Waltz et al. 2000; 
Bennett 2005; Mease 2005). This confirms the selection of the FIQ as primary outcome 
measure. 
Self-reported clinical pain and tenderness are both characteristic and necessary in 
diagnosing Fibromyalgia. Yet, their functional association and how they are related to one 
another is not clear (Jacobs, Rasker et al. 1996). It has been shown that these entities do not 
equally respond to treatment interventions (Gracely, Grant et al. 2003). In this study, clinical 
pain was evaluated with the body diagram of Lautenschläger. The body diagram allows 
calculating a sum score for overall pain intensity that measures generalized pain similar to a 
visual analogue scale (Hassett, Radvanski et al.) that asks for general pain. Tenderness was 
assessed by Pressure Pain Threshold in the M. trapezius region where the EMG-biofeedback 
electrodes were placed. The Total Myalgic Score and the Tender Point Index for all Tender 
Points were not measured. Fibromyalgia patients had not only been found to be more sensitive 
to pressure at Tender Points than healthy controls, but throughout the whole body, for 
example, at the M. trapezius and M. frontalis (Tunks, Crook et al. 1988; Bendtsen, Norregaard 
et al. 1997; Petzke, Clauw et al. 2003). A recent study has noticed that “sham points” had 
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higher pain thresholds than Tender Points, but can be used as an equivalent of the total 
myalgic score that consists in measuring the pain threshold at all Tender Points with 
dolorimeters (Harden, Revivo et al. 2007).  
Although the Short From–36 (SF-36) has not yet been evaluated for responsiveness in 
Fibromyalgia, it can be expected to be sensitive to change such as in studies for somatic and 
psychiatric diseases (Bullinger 1995; Bullinger 1998; Igl, Zwingmann et al. 2006). As already 
mentioned, Fibromyalgia patients frequently suffer from depressive symptoms or unspecific 
psychological distress. Their influence on aetiology, onset and maintenance is widely 
discussed. It has been found that chronic pain patients are more likely to become depressive 
than healthy controls, and that depressed mood correlated with ongoing pain and physical 
impairment in Fibromyalgia (Fishbain, Cutler et al. 1997; Epstein, Kay et al. 1999; Finset, 
Wigers et al. 2004). As EMG-biofeedback was able to reduce depression in patients with 
migraine, this study employed the Beck Depression Inventory and the Global Severity Index 
of the Symptom Checklist 90 Revised (Nestoriuc and Martin 2007). The Beck Depression 
Inventory and the Symptom checklist 90-Revised are widely used to assess depressive 
symptoms and have also been recommended for Fibromyalgia trials (Mease 2005). In total, 
the selected measures in this study covered the most relevant outcome domains of patients 
with Fibromyalgia and have shown sensitivity to change in similar populations. 
 
The generalizability of this study may be limited by the method of recruitment of 
patients. As patients were recruited from the waiting list of the Fibromyalgia day hospital, a 
tertiary care centre, the patients may not be representative for the whole population of patients 
with Fibromyalgia. Patients who apply for the day hospital are usually highly motivated to 
begin a multidisciplinary therapy program. They had several unsuccessful treatments in 
primary care. In addition, patients with Fibromyalgia who are restricted by their disease or by 
comorbidities from participating in the day hospital program may not even have applied for 
this program. Another selection criteria that has become obvious during recruitment was the 
fact that (full-time) working women, in particular those with school children, refused 
participation because they found it to difficult to come to the study centre three times a week 
for three weeks This is may be the reason for the mean age of both groups (IC = 55. 4; CG = 
55. 97) that is higher than in some other studies. Clearly, the study sample did not include the 
whole diversity of patients with Fibromyalgia. However, there is no obvious reason that the 
selection of patients introduced biased to the results.  
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Another limitation of the study is the low number of patients. A sample size calculation was 
performed a priory, but it may have been too optimistic. Due to the small sample size it is 
possible that we have missed effects that are relevant, but too small to become statistically 
significant. However, the set of outcome measures did not even show a trend for a better 
outcome in the treatment group. Some effect sizes for the treatment were positive and others 
were negative. Accordingly, it is unlikely that we missed a relevant beneficial effect on the 
main outcome domains.  
Due to the small sample size, no analyses sample characteristics that may affect the 
response to treatment were performed. In other studies emotional, social and cognitive 
determinants of treatment outcomes were explored (Turk, Okifuji et al. 1998; Giesecke, 
Williams et al. 2003; Muller, Schneider et al. 2007). Psychological distress, for example, was 
found to have more influence on the Tender Point Count than on the pressure pain threshold 
measured by dolorimetry (Petzke, Gracely et al. 2003). Further, high scores of self-reported 
depression seem to impede response to pain treatment (Finset, Wigers et al. 2004). In this 
context, it has been proposed to differentiate between subgroups of Fibromyalgia patients and 
adapt treatment to their characteristics. However, standardized methods for the subgrouping of 
Fibromyalgia patients do not yet exist.  
In this randomized controlled trial (RCT) we aimed to follow the Consort statement for 
randomized controlled trials in both the development of the study design and in the reporting 
of the results (Altmann, Schulz et al. 2007). Besides other criteria of the quality of RCT, 
primary and secondary outcome measures were clearly defined, methods of assessor blinding, 
randomization procedures and sample size calculation were described and effect sizes were 
calculated. Effect sizes ease comparisons with other studies and provide additional 
information of relevant effects besides the p-values of statistical significance. However, 
patients were not blinded to the intervention, because it did not seem feasible to maintain the 
blinding throughout the study 
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9. Conclusion 
In conclusion, in this study EMG-biofeedback training as a single treatment was not effective 
in improving the health status of patients with Fibromyalgia. However, it was not designed to 
answer the question if EMG-biofeedback may amplify the benefits of specific relaxation 
strategies in a more comprehensive intervention. Another question for future research is the 
potentially different outcome of subgroups of patients with certain characteristics. For 
example, poor coping strategies such as catastrophizing have been associated with less 
favourable outcomes and may also predict the effects of EMG-biofeedback either alone or in 
combination with other relaxation strategies. (Hassett, Cone et al. 2000; Edwards, Bingham et 
al. 2006). Analyses of critical sample characteristics that might impede response could help to 
create a basis for more comprehensive individualized treatment modalities. 
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11. Attachement 
11.1. ACR-criteria (Wolfe, Smythe et al. 1990) 
11.1.1. History of widespread pain (presence for at least 3 months) 
Definition: Pain is considered widespread when all of the following are present: pain in the 
left side of the body, pain in the right side of the body, pain above the waist, and pain below 
the waist. In addition, axial skeletal pain (cervical spine or anterior chest or thoracic spine or 
low back) must be present. In this definition, shoulder and buttock pain is considered as pain 
for each involved side. “Low back” pain is considered lower segment pain. 
11.1.2. Pain in 11 of 18 Tender Point sites on digital palpation. 
Occiput: bilateral, at the suboccipital muscle insertions. 
Low cervical: bilateral, at the anterior aspects of the intertransverse spaces at C5 – C7. 
Trapezius: bilateral, at the mid point of the upper border. 
Supraspinatus: bilateral, at origins, above the scapula spine near the medial border. 
Second rib: bilateral, at the second costochondral junctions, just lateral to the junctions on 
upper surfaces. 
Lateral epicondyle: bilateral, 2 cm distal to the epicondyles 
Gluteal: bilateral, in upper outer quadrants of buttocks in anterior fold of muscle. 
Greater trochanter: bilateral, posterior to the trochanteric prominence 
Knee: bilateral, at the medial fat pad proximal to the joint line 
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11.2. Criteria for the diagnosis of Fibromyalgia according to Müller 
and Lautenschläger (Muller and Lautenschlager 1990) 
• Spontaneous pain in the muscles, the tendons, their insertions (typically close to the 
trunk), present for at least three months in 3 different regions 
• Pain on pressure at least at the half of the typical Tender Points (visible pain reaction 
at digital palpation with about 4 kg/cm²) 
• Additional autonomic and functional symptoms, incl. sleep disturbances 
• Psychopathological findings (mental features) 
• Normal finding in routine diagnostic tests 
 
For diagnosis of Fibromyalgia at least 3 of the following autonomic and functional symptoms 
have to be present. 
 Autonomic symptoms 
• Cold hands 
• Sicca complaints (mouth) 
• Hyperhidrosis (hands) 
• Dermographism 
• Orthostatic dysregulation 
• Respiratory arrhythmia 
• Tremor (hands) 
Functional symptoms 
• Sleep disturbance 
• Irritable bowel syndrome 
• Globus feeling 
• Respiratory distress without exertion 
• Paresthesias 
• Cardiac complaints 
• Dysuria and/or dymenorrhoe 
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11.3. Sociodemographic questionnaire 
Bitte beantworten Sie die folgenden Fragen durch Ankreuzen oder geschätzte Zeitangaben. 
1. Welches ist Ihre Muttersprache (hauptsächliche Umgangssprache)? 
      Deutsch             Andere: __________________ 
 
2. Welches ist Ihr höchster Schulabschluss: 
  kein Abschluss 
  Grund- und Hauptschule, Volksschule (Hauptschulabschluss, qualifizierender 
      Hauptschulabschluss) 
  Berufs, Handelsschule, Mittelschule, Realschule, Techniker-Schule (mittlere 
      Reife) 
  Gymnasium, Oberschule (Abitur/Fachabitur) 
  Fachhochschule, Polytechnicum 
  Universität, Hochschule 
 
3. Wie sind Sie zur Zeit beschäftigt, bzw. woher beziehen Sie Ihre Einkünfte? 
  in Ausbildung 
  als Selbständige/r 
  als Arbeiter/in 
  als Beamte/r 
  Invaliden-, Unfallrente 
 
Ruhestandeinkommen: 
  Rente 
  Pension 
  Vorruhestand 
 
anderen Einkommens- oder Unterstützungsarten 
  Arbeitslosengeld 
  Arbeitslosenhilfe 
  Sozialhilfe 
  Hausfrau/-mann 
  Anderes 
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4. Wie viele Wochenstunden sind Sie durchschnittlich in Ihrem Beruf tätig? 
   (auch Hausfrau/-mann)       _____ Stunden pro Woche 
 
5. Wie hoch ist das monatliche Nettoeinkommen, d.h. das verfügbare Haushaltseinkommen, 
das alle Haushaltsmitglieder zusammen nach Abzug von Steuern, Sozialabgaben, Miete 
Abzahlungsverpflichtungen und Versicherungen noch übrig haben: 
  unter 500 € 
  zwischen 500 und 1 000 € 
  zwischen 1 000 und 1 500 € 
  zwischen 1 500 und 2 000 € 
  zwischen 2 000 und 3 000 € 
  über 3 000 € 
 
6. Wie groß ist der Ort in dem Sie wohnen? 
  weniger als 5 000 Einwohner 
  zwischen 5 000 und 50 000 Einwohner 
  zwischen 50 000 und 100 000 Einwohner 
  zwischen 100 000 und 500 000 Einwohner 
  über 500 000 Einwohner 
 
7. Wie viele Personen leben ständig in Ihrem Haushalt, Sie selbst mitgerechnet? 
 Insgesamt ____ Personen, davon 
 Unter 6 Jahre alt                     ____ 
 Zwischen 6 und 15 Jahre ____ 
 Von 15 bis 18 Jahre  ____ 
 Über 18 Jahre   ____ 
 Bei ____ Personen liegen besondere Betreuungsanforderungen (z.B. Behinderungen, 
chronische Erkrankungen) vor.    
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8. Wie häufig verbringen Sie Ihre Freizeit in folgenden Vereinigungen/Gesellschaften? 
 häufig manchmal nie 
Mit karitativer Zielsetzung (z.B. 
Kirchenvorstand) 
   
Mit künstlerischer Zielsetzung (z.B. 
Blaskapelle, Tanzgruppe) 
   
Mit politischer Zielsetzung (z.B. 
Bürgerinitiative, Partei) 
   
Mit sportlicher Zielsetzung (z.B. Tennisclub)    
Mit sonstiger Zielsetzung (z.B. Bridge-Club, 
Gartenverein, Elternbeirat) 
   
 
9. Rauchen Sie zurzeit? 
 Nein     Ja Wenn ja, ____ Zig./Tag      seit ____ Jahren 
 
10. Trinken Sie alkoholische Getränke? 
 Nein     
 Ja  Wenn ja:  gelegentlich         1x täglich         mehrmals täglich 
 
11. Wieviel Zeit verbringen Sie üblicherweise täglich mit Gehen, Fahrradfahren oder 
ähnlichen Tätigkeiten im Freien? 
  keine 
  etwas, aber weniger als 30 Minuten 
  30 bis 60 Minuten 
  über eine Stunde 
 
12. Wie lange treiben Sie gewöhnlich in der Woche Sport (oder irgendeine körperliche 
Aktivität), so dass Sie ins Schwitzen und außer Atem kommen? 
  mehr als 2 Stunden in der Woche 
  1 bis 2 Stunden in der Woche 
  weniger als 1 Stunde in der Woche 
  keine sportliche Betätigung 
 
13. Gab es in den letzten 12 Monaten ein/mehrere Ereignis/se, welche/s Ihr Leben nachhaltig 
beeinflusst haben, z.B. Tod einer vertrauten Person, Scheidung, Umzug, Verlust des 
Arbeitsplatzes, Hochzeit, Geburt eines Kindes/Enkelkindes, Urlaub? 
  Nein 
  Ja wenn ja:  positiv  negativ 
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11.4. German version of the Self-administered Comorbidity 
Questionnaire (SCQ) 
For copyright reasons, this questionnaire cannot be displayed here. 
 
11.5. German version of the Fibromyalgia Impact Questionnaire 
(FIQ) 
For copyright reasons, this questionnaire cannot be displayed here. 
 
11.6. German version of the generic health questionnaire Short-Form 
36 
For copyright reasons, this questionnaire cannot be displayed here. 
 
11.7. Tender Point Score 
For copyright reasons, this questionnaire cannot be displayed here. 
 
11.8. German version of the Beck Depression Inventory 
For copyright reasons, this questionnaire cannot be displayed here. 
 
11.9. German version of the Symptom Checklist 90 Revised 
For copyright reasons, this questionnaire cannot be displayed here. 
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12. Curriculum vitae 
 
 Persönliche Daten 
Name:  Eva Ursula Baumüller 
Geburtstag:    25.03.1981 in Erlangen 
Anschrift:    Fallmerayerstr.21 
   80796 München 
Tel.:   089/32667817 
e-mail:  eva_baumueller@hotmail.com 
Familienstand:  ledig   
 
 
 Ausbildung 
    
Schullaufbahn: 
1987 – 2000   Grundschule und Christoph-Jacob-Treu-Gymnasium in 
Lauf a.d. Peg.  
06/2000  Allgemeine Hochschulreife 
 
Berufsausbildung: 
2000 – 2007  Studium der Humanmedizin an der LMU München 
04/2007  Approbation als Ärztin 
Praktisches Jahr:  Erstes Tertial: Innere Medizin am Hôpital Riviera in Vevey/ Schweiz 
  Zweites Tertial: Psychiatrie in der Psychiatrischen Klinik  
        Nussbaumstrasse der LMU München 
  Drittes Tertial: Chirurgie am Universitätskrankenhaus Gasthuisberg  
                           der Katholischen Universität Leuven/ Belgien 
Famulaturen:  Innere Medizin (Missionsärztliche Klinik Würzburg) 
  Ambulante Anästhesie (Praxis Dr. Müller, München) 
  Tropenmedizin (Instituto „Alexander v. Humboldt“, Hospital 
                            Cayetano Heredía, Lima/Peru) 
  Physikalische Medizin und Rehabilitation (LMU München) 
      Psychiatrie (Max-Planck-Institut für Psychiatrie, München) 
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Zusatzqualifikationen: 
WiSe 2004/05  Propädeutik der Akupunktur I 
SoSe 2003  Tropenmedizin II 
   WiSe 2002/03  Tropenmedizin I 
 
 
 Berufliche Erfahrung 
2003 - 2007 Assistentin in Hyperbarer Sauerstofftherapie (HBO) und 
ambulanter Anästhesie 
 
seit September 2007 Assistenzärztin in der Klinik für Anästhesiologie am 
Klinikum München rechts der Isar der Technischen 
Universität München 
 
 
